The University of Virginia Cancer Center is conducting a clinical research study for patients who are adults ages 18 and over, and have advanced head and neck squamous cell carcinoma cancer. The purpose of this study to evaluate the combination of an experimental drug (pembrolizumab) and chemotherapy (cisplatin) in patients with advanced head and neck squamous cell carcinoma cancer. The safety and effects of the experimental drug combination will be evaluated for this study.

The University of Virginia is conducting a clinical research study for adults ages 18 and over, who have prostate cancer. The purpose of this study is to look at the safety and the maximum tolerated dose through single and multiple dosing of the study drug when given orally to adult male subjects with castration-resistant prostate cancer (CRPC) who have completed at least 4 weeks of prior continuous therapy with fixed stable dose enzalutamide, abiraterone or apalutamide prior to starting study treatment, with no change in dose for at least 2 weeks prior to screening.

The UVA Cancer Center seeks women ages 18 and over who have recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer for a clinical trial. This includes the following histologic types: serous adenocarcinoma (Grade 1, 2, or 3/ high grade or low grade), endometrioid adenocarcinoma, mucinous adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial adenocarcinoma, transitional cell carcinoma, or adenocarcinoma not otherwise specified.

The University of Virginia is conducting a clinical research study for adults ages 18 and over, who have newly diagnosed Mantle Cell Lymphoma (MCL). If you enroll in this study you will be put on 1 of 3 combination of drugs. The purpose of this study is to find out if one of the three drug combinations is better or worse than the usual approach for your MCL.

UVA Health System, Department of Radiology, seeks men and women who are healthy, and those with lung cancer or liver cancer for a research study. The purpose of the study is to improve imaging techniques of soft-tissue in the lungs and abdomen using Magnetic Resonance Imaging (MRI). The study involves a physical exam along with the MRI. Study procedures can be completed in one 1-2hour visit.

Healthy volunteers must be 18-75 years old; Volunteers with lung or liver cancer must be 21-75 years old.

Study-related MRI is provided free of charge.

The UVA Cancer Center has a clinical trial for adults ages 18 and over who have an advanced relapsed solid tumor, ovarian clear cell carcinoma or endometrial carcinoma. You will be eligible if you have already been treated with standard therapy and your tumor is now growing.

UVA Dermatology Department seeks ANYONE ages 12 and up with psoriasis for a research study. The purpose of the study is to compare the effectiveness of home vs. office based phototherapy treatment of psoriasis.

You may be eligible for this study if:
• You are willing and able to receive phototherapy treatment at home or in the clinic 3 times a week for 12 weeks
• You are at least 12 years old
• You have never had phototherapy treatment or have not had phototherapy treatment for at least 2 weeks

The University of Virginia Cancer Center is conducting a clinical research study for patients who are adults ages 18 and over, and have a breast, non-small cell lung cancer, bladder, cervical, or colorectal cancers. The purpose of this study to evaluate an investigational drug (AN0025) plus an FDA approved drug (pembrolizumab) in patients with the 5 solid tumor cancer types. The experimental drug dose, safety, and the effects of the drug will be evaluated for this study.

The University of Virginia Cancer Center is conducting a clinical research study for adults ages 18 and over who are receiving treatment with cemiplimab or will soon start that treatment for advanced Cutaneous Squamous Cell Carcinoma (CSCC). The purpose of this research study is to understand the long-term effectiveness and safety of this drug in patients diagnosed with advanced CSCC.

Participation will last for up to 3 years. This study will follow your standard care and you will be asked to complete questionnaires throughout the duration of your participation.

The University of Virginia Cancer Center is conducting a clinical research study for adults ages 18 and over who have Cutaneous Squamous Cell Carcinoma (CSCC) and have had surgery and radiation therapy. The purpose of this research study is to determine if an immunotherapy drug (cemiplimab) will prevent cutaneous squamous cell cancer from returning after surgery and radiation.